Specifications of a continual reassessment method design for phase I trials of combined drugs

被引:29
作者
Wages, Nolan A. [1 ]
Conaway, Mark R. [1 ]
机构
[1] Univ Virginia, Dept Publ Hlth Sci, Div Translat Res & Appl Stat, Charlottesville, VA USA
关键词
continual reassessment method; dose finding; maximum tolerated dose; phase I trials; partial ordering; drug combination; ADVANCED SOLID TUMORS; COMBINATIONS;
D O I
10.1002/pst.1575
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In studies of combinations of agents in phase I oncology trials, the dose-toxicity relationship may not be monotone for all combinations, in which case the toxicity probabilities follow a partial order. The continual reassessment method for partial orders (PO-CRM) is a design for phase I trials of combinations that leans upon identifying possible complete orders associated with the partial order. This article addresses some practical design considerations not previously undertaken when describing the PO-CRM. We describe an approach in choosing a proper subset of possible orderings, formulated according to the known toxicity relationships within a matrix of combination therapies. Other design issues, such as working model selection and stopping rules, are also discussed. We demonstrate the practical ability of PO-CRM as a phase I design for combinations through its use in a recent trial designed at the University of Virginia Cancer Center. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 18 条
[11]   Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors [J].
Patnaik, A ;
Warner, E ;
Michael, M ;
Egorin, MJ ;
Moore, MJ ;
Siu, LL ;
Fracasso, PM ;
Rivkin, S ;
Kerr, I ;
Litchman, M ;
Oza, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) :3677-3689
[12]   Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase:: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors [J].
Ranson, M ;
Middleton, MR ;
Bridgewater, J ;
Lee, SM ;
Dawson, M ;
Jowle, D ;
Halbert, G ;
Waller, S ;
McGrath, H ;
Gumbrell, L ;
McElhinney, RS ;
Donnelly, D ;
McMurry, TBH ;
Margison, GP .
CLINICAL CANCER RESEARCH, 2006, 12 (05) :1577-1584
[13]   Consistency of continual reassessment method under model misspecification [J].
Shen, LZ ;
OQuigley, J .
BIOMETRIKA, 1996, 83 (02) :395-405
[14]   Using the time-to-event continual reassessment method in the presence of partial orders [J].
Wages, Nolan A. ;
Conaway, Mark R. ;
O'Quigley, John .
STATISTICS IN MEDICINE, 2013, 32 (01) :131-141
[15]   Dose-finding design for multi-drug combinations [J].
Wages, Nolan A. ;
Conaway, Mark R. ;
O'Quigley, John .
CLINICAL TRIALS, 2011, 8 (04) :380-389
[16]   Continual Reassessment Method for Partial Ordering [J].
Wages, Nolan A. ;
Conaway, Mark R. ;
O'Quigley, John .
BIOMETRICS, 2011, 67 (04) :1555-1563
[17]   A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents [J].
Yin, Guosheng ;
Yuan, Ying .
BIOMETRICS, 2009, 65 (03) :866-875
[18]   Bayesian dose finding in oncology for drug combinations by copula regression [J].
Yin, Guosheng ;
Yuan, Ying .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2009, 58 :211-224